The role of CDK4/6 inhibition in breast cancer

Oncologist

Volumn 20, Issue 5, 2015, Pages 483-490

  Murphy, Conleth G ^a   Dickler, Maura N ^b  

^a BON SECOURS HOSPITAL   (Ireland)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Abemaciclib; Breast neoplasms; Flavopiridol; Inhibitors of cyclin dependent kinase 4 proteins; LEE011; Palbociclib

Indexed keywords

ABEMACICLIB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLAVOPIRIDOL; FULVESTRANT; LETROZOLE; PALBOCICLIB; RIBOCICLIB; AMINOPYRIDINE DERIVATIVE; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; FLAVONOID; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; FEMALE; GENETICS; PATHOLOGY;

AMINOPYRIDINES; BREAST NEOPLASMS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DNA BREAKS, DOUBLE-STRANDED; ESTROGEN RECEPTOR ALPHA; FEMALE; FLAVONOIDS; HUMANS; PIPERAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PURINES; PYRIDINES;

EID: 84929075292     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0443     Document Type: Article

References (82)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-674.
3. Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246:603-608.
4. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-291.
5. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995;20:187-190.
6. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
7. Dean JL, Thangavel C, McClendon AK et al. Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene 2010;29:4018-4032.
8. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-1783.
10. Bowe DB, Kenney NJ, Adereth Y et al. Suppression of neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002;21:291-298.
11. Landis MW, Pawlyk BS, Li T et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006;9: 13-22.
12. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-1021.
13. Yu Q, Sicinska E, Geng Y et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006;9:23-32.
14. Reddy HK, Mettus RV, Rane SG et al. Cyclindependent kinase 4 expression is essential for neuinduced breast tumorigenesis. Cancer Res 2005;65: 10174-10178.
15. Choi YJ, Li X, Hydbring P et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012;22:438-451.
16. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
17. Casimiro MC, Crosariol M, Loro E et al. ChIP sequencing of cyclinD1reveals a transcriptional role in chromosomal instability in mice. J Clin Invest 2012;122:833-843.
18. Pestell RG. New roles of cyclin D1. Am J Pathol 2013;183:3-9.
19. Kollmann K, Heller G, Schneckenleithner C et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013;24:167-181.
20. Dinaciclib and epirubicin hydrochloride in treating patients with metastatic triple-negative breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT01624441. Accessed November 4, 2014.
21. Phase I/Ib dose-escalation of dinaciclib with weekly paclitaxel for advanced solid tumor malignancies & assessment of MYC oncogene overexpression. Available at http://www.clinicaltrials.gov/ct2/show/NCT01676753. Accessed November 4, 2014.
22. Criscitiello C, Viale G, Esposito A et al. Dinaciclib for the treatment of breast cancer. Expert Opin Investig Drugs 2014;23:1305-1312.
23. Benson C, White J, De Bono J et al. Aphase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br JCancer 2007;96:29-37.
24. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011;137:1409-1418.
25. Search results: Roscovitine AND breast cancer. Available at http://clinicaltrials.gov/ct2/results?term5roscovitine1AND1breast1cancer. Accessed November 4, 2014.
26. Cicenas J, Kalyan K, Sorokinas A et al. Highlights of the latest advances in research on CDK inhibitors. Cancers (Basel) 2014;6:2224-2242.
27. Sedlacek H, Czech J, Naik R et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996;9:1143-1168.
28. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002;62:1707-1717.
29. Gallorini M, Cataldi A, di Giacomo V. Cyclindependent kinase modulators and cancer therapy. BioDrugs 2012;26:377-391.
30. Fornier MN, Rathkopf D, Shah M et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13:5841-5846.
31. Altucci L, Addeo R, Cicatiello L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G (1)-arrested human breast cancer cells. Oncogene 1996;12:2315-2324.
32. Altucci L, Addeo R, Cicatiello L et al. Estrogen induces early and timed activation of cyclindependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 1997;138:978-984.
33. Prall OW, Sarcevic B, Musgrove EA et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclinD1expressionanddecreased cyclindependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272:10882-10894.
34. Watts CK, Brady A, Sarcevic B et al. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclindependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9:1804-1813.
35. Casimiro MC, Wang C, Li Z et al. Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Mol Endocrinol 2013;27:1415-1428.
36. Thangavel C, Dean JL, Ertel A et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrinetherapy-resistant breast cancer. Endocr Relat Cancer 2011;18:333-345.
37. Finn RS, Dering J, Conklin D et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
38. Fry DW, Harvey PJ, Keller PR et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3: 1427-1438.
39. Michaud K, Solomon DA, Oermann E et al. Pharmacologic inhibition ofcyclin-dependent kinases 4and6arreststhegrowthofglioblastomamultiforme intracranial xenografts. Cancer Res 2010;70:3228-3238.
40. Roberts PJ, Bisi JE, Strum JC et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012;104:476-487.
41. Schwartz GK, LoRusso PM, Dickson MA et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011;104:1862-1868.
42. Flaherty KT, Lorusso PM, Demichele A et al. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-576.
43. DeMichele A, Sanders Clark A, Heitian D et al. A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer. J Clin Oncol 2013;31(suppl):519a.
44. Cohen MH, Johnson JR, Li N et al. Approval summary: Letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res 2002;8:665-669.
45. Slamon DJ, Hurvitz SA, Applebaum S et al. Phase I study of PD-0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for firstline treatment of patients with ER-positive, HER2-negative breast cancer. J Clin Oncol 2010;28(suppl): 3060a.
46. Finn RS, Crown JP, Boer K et al. Preliminary results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with post-menopausal, ER-positive, HER2-negative advanced breast cancer. Poster presented at: San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, TX.
47. Finn RS, Crown JP, Boer K et al. Results of a randomized phase II study of PD-0332991, a cyclin dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER1/HER2-advanced breast cancer (BC) [abstract 1000]. Ann Oncol 2012;23(suppl 2):ii43-ii45.
48. Finn RS, Crown JP, Lang I et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16:25-35.
49. Pfizer to submit palbociclib New Drug Application with FDA based on final results of PALOMA-1. Available at http://www.pfizer.com/news/pressrelease/press-release-detail/pfizer_to_submit_palbociclib_new_drug_application_with_fda_based_on_final_results_of_paloma_1. Accessed November 4, 2014.
50. NDA 207103: Accelerated approval. Available at http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207103Orig1s000ltr.pdf.Accessed February 24, 2015.
51. Ibrance (palbociclib) [prescribing information]. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf. Accessed February 24, 2015.
52. A study of palbociclib (PD-0332991) 1 letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER1/HER2-advanced breast cancer (PALOMA-2). Available at http://clinicaltrials.gov/ct2/show/NCT01740427. Accessed November 4, 2014.
53. Palbociclib (PD0332991) combined with fulvestrant in hormone receptor1 HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3). Available at http://clinicaltrials.gov/ct2/show/NCT01942135. Accessed November 4, 2014.
54. Search results: Palbociclib AND breast cancer. Available at http://clinicaltrials.gov/ct2/results?term5palbociclib1AND1breast1cancer. Accessed November 4, 2014.
55. Knudsen E, Cox D, Franco J et al. Targeting CDK4/6 in HER2 positive breast cancer: Therapeutic effect, markers and combination strategies. Ann Oncol 2014;25(suppl 1):i21.
56. Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2- targeted therapies in preclinical breast cancer models. Genes Cancer 2014;5:261-272.
57. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
58. Phase Ib study of PD-0332991 in combination with T-DM1 (trastuzumab-DM1). Available at http://clinicaltrials.gov/ct2/show/NCT01976169. Accessed November 4, 2014.
59. Pediatric oncology subcommittee of the oncologic drugs advisory committee briefing document: LEE011. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM373175.pdf. Accessed November 4, 2014.
60. Kim S, Loo A, Chopra R et al. LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther 2013;12(suppl):PR02a.
61. Infante JR, Shapiro G, Witteveen P et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 2014;32(suppl):2528a.
62. Search results: LEE011 | open studies. Available at http://clinicaltrials.gov/ct2/results?term5LEE011&recr5Open. Accessed November 4, 2014.
63. Study of LEE011, BYL719 and letrozole in advanced ER1 breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT01872260. Accessed November 4, 2014.
64. Phase Ib/II trial of LEE011 with everolimus (RAD001) and exemestane in the treatment of ER1 HER2- advanced breast cancer. Available at http://clinicaltrials.gov/ct2/show/NCT01857193. Accessed November 4, 2014.
65. Vora SR, Juric D, Kim N et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014;26:136-149.
66. Bardia A, Modi S, Chavez-Mac Gregor M et al. Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER1 /HER2-metastatic breast cancer. J Clin Oncol 2014; 32(suppl):535a.
67. Munster PN, Paige Hamilton E, Franklin C et al. Phase lb studyof LEE011 and BYL719 incombination with letrozole in estrogen receptor-positive, HER2-negative breastcancer (ER1,HER2- BC). JClin Oncol 2014;32(suppl):533a.
68. Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer.(MONALEESA-2). Available at http://clinicaltrials.gov/ct2/show/NCT01958021. Accessed November 4, 2014.
69. A pharmacodynamics pre-surgical study of LEE011 in early breast cancer patients (MONALEESA-1). Available at http://clinicaltrials.gov/ct2/show/NCT01919229. Accessed November 4, 2014.
70. Gelbert LM, Cai S, Lin X et al. Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity. Mol Cancer Ther 2011;10(suppl):B233a.
71. Sanchez-Martinez C, Gelbert LM, Shannon H et al. LY2835219, a potent oral inhibitor of the cyclindependent kinases4and 6(CDK4/6) that crossesthe blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts. Mol Cancer Ther 2011;10(suppl):B234a.
72. Dempsey JA, Chan EM, Burke TF et al. LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. Cancer Res 2013;73(suppl):LB-122a.
73. Shapiro G, Rosen LS, Tolcher AW. A first-inhuman phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol 2013;31(suppl):2500a.
74. Patnaik A, Rosen LS, Tolaney SM et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer [abstract CT232]. Presented at: American Association for Cancer Research annual meeting; April 5-9, 2014; San Diego, CA.
75. Patnaik A, Rosen LS, Tolaney SM et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combinationwith fulvestrant for patients with hormone receptor positive (HR1) metastatic breast cancer. J Clin Oncol 2014;32(suppl):534a.
76. Search results: LY2835219 | open studies. Available at http://clinicaltrials.gov/ct2/results?term5LY2835219&recr5Open. Accessed November 4, 2014.
77. A study of nonsteroidal aromatase inhibitors plus abemaciclib (LY2835219) in postmenopausal women with breast cancer (MONARCH 3). Available at http://clinicaltrials.gov/ct2/show/NCT02246621. Accessed November 4, 2014.
78. A study of LY2835219 (abemaciclib) in combination with therapies for breast cancer that has spread. Available at http://clinicaltrials.gov/ct2/show/NCT02057133. Accessed November 4, 2014.
79. A study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positiveHER2negative breastcancer(MONARCH2). Available at http://clinicaltrials.gov/ct2/show/NCT02107703. Accessed November 4, 2014.
80. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem 2012;287:29075-29087.
81. Pierce AJ, Stark JM, Araujo FD et al. Doublestrand breaks and tumorigenesis. Trends Cell Biol 2001;11:S52-S59.
82. Pfizer breast cancer drug gets early FDA approval. Available at http://finance.yahoo.com/news/pfizer-breast-cancer-drug-gets-225132522.html. Accessed February 24, 2015.